New Study Data Presented on Sunridge International's PNT Treatment

FOUNTAIN HILLS, Ariz., May 19 /PRNewswire-FirstCall/ -- Sunridge International (OTC Bulletin Board: SNDZ), announced today that earlier this month, results were presented on a six-month independent study on PNT's effectiveness on ocular hypertension patients.

The presentation given at ARVO (Association for Research in Vision and Ophthalmology) showed, as in other studies preformed, that PNT is a safe and effective treatment for glaucoma and ocular hypertension. To date, approximately a dozen studies have been performed worldwide. "It's important to understand," states G. Richard Smith, president of Sunridge, "that these studies show PNT as an effective, safe and cost efficient treatment. This point has been proven time and time again, and has allowed us to receive approval throughout Europe, Asia and Canada to market our product and perform this much needed treatment on patients."

Mr. Smith goes on to say, "This study however, was different than most, because it dealt with ocular hypertension patients only. This is important because it is helping Sunridge to open a whole new market for our product line, a market 10 times larger than the present glaucoma market."

Studies show that 10 people out of every 100 over the age of 40 will have ocular hypertension, yet only 1 out of the 100 will have glaucoma. It has been shown that if ocular hypertension patients were treated, and inter ocular pressure (IOP) reduced, that only half or 5% would develop glaucoma. Unfortunately, given the side effect profile of current glaucoma therapies, doctors are reluctant to treat this group of patients. Doctors feel that exposing 90% of the patients to the side effect risks, do not outweigh the benefit to the 5% being helped. This is a view shared by most doctors and healthcare professionals worldwide.

"It is studies like this, reinforced by scientific data, that are going to allow Sunridge International's PNT therapy to enter this virtually untapped market. PNT has been proven to be a safe and effective treatment with little or no adverse side effects and has little or no competition in this area. I further expect that the move into this market with our technology will have a very dramatic effect upon our sales and future profitability," states G. Richard Smith.

To view abstracts, studies and peer review journal publications on PNT, visit the "Publications" page on our website, www.oi-pnt.com.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.

SOURCE Sunridge International